L-Valacyclovir Hydrochloride

Category	Herpes simplex Virus (HSV)
CAS	124832-27-5
Description	Valaciclovir HCl is an antiviral drug used in the management of herpes simplex, herpes zoster, and herpes B.

Quotation Now

Product Information

Synonyms	Valacyclovir hydrochloride; Valacyclovir HCl
IUPAC Name	2-[(2-amino-6-oxo-1H-purin-9-yl)methoxy]ethyl (2S)-2-amino-3-methylbutanoate;hydrochloride
Molecular Weight	360.8
Molecular Formula	C13H20N6O4.HCl
Canonical SMILES	CC(C)C(C(=O)OCCOCN1C=NC2=C1NC(=NC2=O)N)N.Cl
InChI	InChI=1S/C13H20N6O4.ClH/c1-7(2)8(14)12(21)23-4-3-22-6-19-5-16-9-10(19)17-13(15)18-11(9)20;/h5,7-8H,3-4,6,14H2,1-2H3,(H3,15,17,18,20);1H/t8-;/m0./s1
InChIKey	ZCDDBUOENGJMLV-QRPNPIFTSA-N
Boiling Point	588.4°C at 760 mmHg
Melting Point	170-172°C
Flash Point	309.7°C
Purity	>98%
Density	1.55g/cm3
Solubility	In vitro: 10 mM in DMSO
Appearance	Solid Powder
Storage	Powder: -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month
Complexity	483
Exact Mass	360.1312809
Index Of Refraction	1.673
In Vitro	Valacyclovir hydrochloride (Valaciclovir hydrochloride; VACV) uptake was concentration dependent and saturable with a Michaelis-Menten constant and maximum velocity of 1.64 mM and 23.34 nmol/mg protein/5 min, respectively. A very similar Km value was obtained in hPEPT1/CHO cells and in rat and rabbit tissues and Caco-2 cells, suggesting that hPEPT1 dominates the intestinal transport properties of VACV in vitro.
In Vivo	For treatment of a first episode of genital herpes, a large comparative trial has shown that Valacyclovir hydrochloride (1 g twice a day) is as effective as acyclovir (200 mg five times a day) when given for 10 days. For treating recurrences, two trials show that valacyclovir is as effective as acyclovir (200 mg five times a day) with a treatment period of 5 days. A daily dose of 1 g of valacyclovir is as effective as 2 g daily. Valacyclovir can be administered once a day. The concentrations of acyclovir in serum and CSF were measured at steady state after 6 days of oral treatment with 1,000 mg of valacyclovir three times a day. EC50 values of PE and AC in 3T3 cells were 0.02 and 0.01 ug/ml, while values in BHK cells were 0.2 and 0.03 ug/ml. Treatment of infected immunosuppressed mice and FA and VA (b.i.d., 5.5 days) reduced the proportion with erythema from 100% to 24% and 38%, and eliminated ear paralysis, ear lesions (vesicles, etc) and death. Virus was absent from ear and brainstem by day 6, but reappeared after discontinuation in mice treated with VA.
PSA	151.14000
Target	HSV; Antibiotic
Vapor Pressure	7.95E-14mmHg at 25°C